CPR Therapeutics Promotes David Gaddy to CEO

Early-stage medtech startup company funded by N.S.F and N.I.H, CPR Therapeutics has promoted Chief Technology Officer David (CTO) Gaddy to Chief Executive Officer (CEO).
 
CPR Therapeutics is working to develop next-generation, multimodal cardiopulmonary resuscitation (CPR) treatments. Currently, no device is more effective than manual chest compressions. Cardiac Arrest is one of the leading causes of death worldwide and intact survival after cardiac arrest is below 10% in most communities. 
 
Gaddy is an engineer with over 15 years of experience in the medical device industry, having led many teams to develop breakthrough technologies. CPR Therapeutics believes that Gaddy is well-qualified to lead the company in its next phase of growth and innovation. 
 
Founder and president of the company, Norman Paradis said, “We could not be more excited to have Dave lead our efforts. His background, skill set and temperament are extraordinary and we have learned firsthand during his time as CTO that he is a wonderful fit with all members of our team as well as the company’s key stakeholders.”
 
Paradis will assume the role of Chief Medical Officer and Gaddy will serve as both CTO and CEO. 
 
“I am honored to be asked to be CEO at CPR Therapeutics Inc. and continue our mission to save lives through the development of this breakthrough technology,” Gaddy commented. “Our CPR-T Multimodal System ™ is set to revolutionize the treatment of cardiac arrest. I can’t think of a more impactful medical device addressing a major unmet need.”
 
As CTO and CEO, Gaddy has made major advancements in the development of automated CPR devices to enhance blood flow and the efficacy of electrical countershock. This serves as a safer and more effective alternative to existing CPR methods.